Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

IXHL vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 2–5 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: IXHL 2 – 3 ATYR (1 Tie) Matrix Metrics: IXHL 5 – 2 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Incannex Healthcare Limited (IXHL) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IXHL carries a Unified Composite Score of 52.3/100 (HOLD) at $1.75 (3.8x Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While IXHL currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: IXHL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IXHL vs ATYR
IXHL NASDAQ
Incannex Healthcare Limited American Depositary Shares
Pharmaceutical Preparations
$1.75
-9.33% 1D
Market Cap $24.7M
TTM Revenue N/A
Forward P/E 3.8x
Beta / 30D Vol 1.38β · 62% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 18
RSI-14: 18.0 · SMA20: $2.34 · SMA50: $2.86
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.57β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (IXHL 2 – 3 ATYR)

Columns: Metric · IXHL · ATYR
1. Valuation Multiples IXHL
Forward P/E 3.8x N/M
Trailing P/E 3.8x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ATYR
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $24.7M $15.6M
3. Profitability & Quality IXHL
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -47.8% -93.7%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.37 Book/Sh · -47.8% ROE $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 154.5% (36th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IXHL (5) vs ATYR (2)
Institutional Metric IXHL ATYR Criterion Row Edge
Market Capitalization
Scale
$24.7M $15.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
3.8x N/M Lower Multiple IXHL
Forward P/E Ratio
Valuation
3.8x N/M Lower Multiple IXHL
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth ATYR
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-47.8% -93.7% Higher ROE IXHL
52-Week Range Position
Momentum
25% ($0–$6) 60% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
1.38β · 62% Vol -9.57β · 13806% Vol Lower Realized Risk IXHL
Unified Institutional Score
Composite Signal
52.3 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite IXHL
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.37 Book/Sh · -47.8% ROE) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2749.64 pp
IXHL: -36.59% · ATYR: +2713.05%
3M Horizon ATYR +855.66 pp
IXHL: -49.13% · ATYR: +806.53%
6M Horizon ATYR +952.7 pp
IXHL: -52.7% · ATYR: +900.0%
1Y Horizon ATYR +144.27 pp
IXHL: +397.16% · ATYR: +541.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IXHL vs ATYR. Trailing 12-month operating profitability (IXHL 0.0% vs ATYR 0.0%) and valuation multiples (IXHL 3.8x vs ATYR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IXHL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-47.8% · 3.8x
ATYR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-93.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IXHL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IXHL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IXHL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $24.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IXHL vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Incannex Healthcare Limited (IXHL) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IXHL carries a Unified Composite Score of 52.3/100 (HOLD) at $1.75 (3.8x Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IXHL currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: IXHL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATYR leads the Growth & Scale pillar: IXHL posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IXHL generates N/A in USD-normalized revenue versus N/A for ATYR. In operating R&D and SG&A reinvestment, IXHL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

IXHL screens cheaper on headline valuation multiples. IXHL trades at 3.8x Forward P/E, 3.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IXHL (-47.8% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, IXHL carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 62% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.